Group 1 - APEX Tech Acquisition, TRG Latin America Acquisitions, and Fortress Value Acquisition V collectively raised $550 million in the US stock market on February 26, 2026 [1][2] - APEX Tech Acquisition, led by Shaoren Liu from China, targets US companies with no industry restrictions, focusing on cash flow, technological leadership, and management teams [2] - TRG Latin America Acquisitions, initiated by Nicolas Rohatyn, focuses on growth sectors in Latin America, particularly Argentina, targeting energy, mining, agriculture, and technology [2] - Fortress Value Acquisition V, led by Andrew McKnight, has no geographic or industry restrictions and aims to find companies that can provide attractive risk-adjusted returns [2] Group 2 - Generate Biomedicines plans to raise $400 million by issuing 25 million shares at $16 each, with the funds allocated for clinical trials, platform innovation, candidate drug development, and general corporate purposes [4] - Generate Biomedicines is a tech-driven biopharmaceutical company utilizing an AI platform to design, test, and advance new drug candidates to address biological challenges that traditional technologies struggle with [4] - Projected revenues for Generate Biomedicines are $20.46 million and $31.89 million for 2024 and 2025, respectively, with corresponding net losses of $181 million and $223 million [4]
美股迎3只新股上市 今晚还有1只